Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. (NYSE: HTGC) generates news that reflects its role as a specialty finance company focused on senior secured venture growth loans to high-growth, innovative companies in technology and life sciences industries. Company announcements and regulatory filings provide insight into its lending activity, capital markets presence, credit ratings, and shareholder distributions, all of which are relevant to investors tracking HTGC stock.
News about Hercules Capital often covers financing transactions with venture-backed companies, such as growth facilities and term loans that support corporate expansion, product development, or balance sheet restructuring. Public releases also highlight the company’s position as a financing partner to businesses in areas like finance automation, mental health therapeutics, and multifamily housing technology, illustrating how its venture growth loans are deployed in practice.
Another recurring theme in Hercules Capital’s news flow is its financial performance and distributions. The company reports quarterly results, including total investment income and other performance metrics, through earnings releases and related conference calls. It also announces quarterly cash distributions, describing its variable distribution policy and the breakdown of base and supplemental distributions, along with key record and payment dates.
Credit quality and ratings updates are also part of the HTGC news stream. Rating agencies such as Moody’s Investors Service and Kroll Bond Rating Agency have issued reports upgrading or affirming Hercules Capital’s investment grade ratings, citing factors such as its long operating history as a business development company, focus on senior secured venture debt, leverage profile, and access to capital markets.
For investors and analysts, following Hercules Capital news can provide context on its lending pipeline, portfolio activity, distribution decisions, and external credit assessments. This page aggregates these updates so readers can review company-specific developments and related commentary in one place.
On November 16, 2022, Silicon Valley Bank and Hercules Capital announced a $300 million credit facility for Oak Street Health (NYSE: OSH). This financing aims to support Oak Street's operational and strategic initiatives over several years. The partnership reflects strong relationships built over the years. Oak Street Health focuses on value-based primary care for Medicare-eligible patients, particularly those in underserved communities. The collaboration underlines both banks' commitment to healthcare innovation and Oak Street's growth.
Hercules Capital, Inc. (NYSE: HTGC) has announced the participation of its executive management team in several upcoming financial community events. These include the Jefferies BDC Summit and FitchRatings BDC Conference on November 16, 2022, followed by the JMP Securities Financial Services and Real Estate Conference on November 17, 2022. Hercules Capital, the largest specialty financing provider, has committed over $16 billion to more than 600 companies since its inception in December 2003, focusing on senior secured venture growth loans for innovative sectors.
Hercules Capital, Inc. (NYSE: HTGC) reported a record total gross debt and equity commitments of $2.48 Billion for Q3 2022, with gross fundings reaching $1.10 Billion. The company saw a net debt portfolio growth of $465.1 Million and total investment income increased by 20% year-over-year to $84.2 million. Hercules also announced a net investment income of $0.39 per share, covering the increased base distribution payout of $0.36.
Undistributed earnings stand at $134.1 Million.
Bright Machines has secured $132M in its latest funding round, comprised of $100M in equity led by Eclipse Ventures and $32M in debt from Silicon Valley Bank (NASDAQ: SIVB) and Hercules Capital (NYSE: HTGC). This funding aims to enhance the company's software-defined manufacturing capabilities, expand into new industry verticals, and develop additional service offerings. With this round, Bright Machines' total funding since 2018 reaches $330M, positioning it for continued growth in the $250B industrial automation market.
Tricida, Inc. (NASDAQ: TCDA) announced a $125 million debt facility with Hercules Capital, Inc. (NYSE: HTGC). Of this, $100 million is available for Tricida upon meeting certain milestones. This financing aims to support the upcoming NDA resubmission and FDA approval for their drug, veverimer, designed to treat chronic kidney disease (CKD). The loan allows for interest-only payments until August 2024, with possible extensions based on FDA decisions. This partnership is intended to provide non-dilutive capital for Tricida's ongoing development of veverimer.
Hercules Capital, Inc. (NYSE: HTGC) has scheduled its third quarter 2022 financial results conference call for November 2, 2022, at 2:00 p.m. PT (5:00 p.m. ET). Financial results will be released after market close on the same day. The company is a leader in providing senior secured venture growth loans, having committed over $15 billion to more than 590 companies since its inception in December 2003. Investors can access a live webcast of the call on their website, with an archived version available for 30 days.
Hercules Capital, Inc. (NYSE: HTGC) has announced a supplemental cash distribution of $0.15 per share, set to be paid on November 17, 2022, following the record date of November 10, 2022. This distribution is in addition to the regular quarterly cash distribution of $0.36 per share for Q3 2022. The supplemental distribution is derived from undistributed taxable income as of September 30, 2022. Hercules' Board aims to distribute approximately 90% to 100% of its taxable income annually.
Hercules Capital (NYSE: HTGC) has declared a third-quarter 2022 cash distribution of $0.36 per share, with key dates of record on November 10, 2022 and payment on November 17, 2022. The company follows a variable distribution policy, aiming to distribute up to 100% of its taxable income for the year. For Q3 2022, 100% of the declared distributions were from current earnings. Additionally, 87.1% of these distributions qualify as “Qualified Interest Income” exempt from U.S. withholding tax for foreign shareholders.
Hercules Capital, Inc. (NYSE: HTGC) announced that Kroll Bond Rating Agency reaffirmed its investment grade corporate and credit rating at BBB+ with a stable outlook. This rating underscores Hercules' effective venture capital lending strategy and the strong management team's capabilities. The rating reflects the company's focus on senior secured debt investments in technology and life sciences, minimal non-accruals, and solid capital market access. Since its inception, Hercules has committed over $15 billion to more than 590 companies, establishing itself as a leading finance provider.
Provention Bio (Nasdaq: PRVB) announced a term loan facility worth up to $125 million with Hercules Capital (NYSE: HTGC) to bolster its financial standing ahead of the potential commercial launch of teplizumab. The loan is structured in five tranches, with an initial draw of $25 million at closing and the possibility of further disbursements contingent on FDA approval and achievement of specific milestones. This financing aims to enhance the development of therapies for type 1 diabetes and improve the lives of affected individuals.